Literature DB >> 21205042

Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.

John H Halpern1, Andrea R Sherwood, James I Hudson, Staci Gruber, David Kozin, Harrison G Pope.   

Abstract

AIMS: In field studies assessing cognitive function in illicit ecstasy users, there are several frequent confounding factors that might plausibly bias the findings toward an overestimate of ecstasy-induced neurocognitive toxicity. We designed an investigation seeking to minimize these possible sources of bias.
DESIGN: We compared illicit ecstasy users and non-users while (1) excluding individuals with significant life-time exposure to other illicit drugs or alcohol; (2) requiring that all participants be members of the 'rave' subculture; and (3) testing all participants with breath, urine and hair samples at the time of evaluation to exclude possible surreptitious substance use. We compared groups with adjustment for age, gender, race/ethnicity, family-of-origin variables and childhood history of conduct disorder and attention deficit hyperactivity disorder. We provide significance levels without correction for multiple comparisons.
SETTING: Field study. PARTICIPANTS: Fifty-two illicit ecstasy users and 59 non-users, aged 18-45 years. MEASUREMENTS: Battery of 15 neuropsychological tests tapping a range of cognitive functions.
FINDINGS: We found little evidence of decreased cognitive performance in ecstasy users, save for poorer strategic self-regulation, possibly reflecting increased impulsivity. However, this finding might have reflected a pre-morbid attribute of ecstasy users, rather than a residual neurotoxic effect of the drug.
CONCLUSIONS: In a study designed to minimize limitations found in many prior investigations, we failed to demonstrate marked residual cognitive effects in ecstasy users. This finding contrasts with many previous findings-including our own-and emphasizes the need for continued caution in interpreting field studies of cognitive function in illicit ecstasy users.
© 2010 The Authors, Addiction © 2010 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205042      PMCID: PMC3053129          DOI: 10.1111/j.1360-0443.2010.03252.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  47 in total

1.  Cannabis, cognition, and residual confounding.

Authors:  Harrison G Pope
Journal:  JAMA       Date:  2002-03-06       Impact factor: 56.272

2.  Neuropsychological performance in long-term cannabis users.

Authors:  H G Pope; A J Gruber; J I Hudson; M A Huestis; D Yurgelun-Todd
Journal:  Arch Gen Psychiatry       Date:  2001-10

3.  Early-onset cannabis use and cognitive deficits: what is the nature of the association?

Authors:  Harrison G Pope; Amanda J Gruber; James I Hudson; Geoffrey Cohane; Marilyn A Huestis; Deborah Yurgelun-Todd
Journal:  Drug Alcohol Depend       Date:  2003-04-01       Impact factor: 4.492

Review 4.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

Review 5.  Altered states: the clinical effects of Ecstasy.

Authors:  J C Cole; H R Sumnall
Journal:  Pharmacol Ther       Date:  2003-04       Impact factor: 12.310

6.  A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users.

Authors:  Maartje M L de Win; Liesbeth Reneman; Gerry Jager; Erik-Jan P Vlieger; Sílvia D Olabarriaga; Cristina Lavini; Ivo Bisschops; Charles B L M Majoie; Jan Booij; Gerard J den Heeten; Wim van den Brink
Journal:  Neuropsychopharmacology       Date:  2006-11-01       Impact factor: 7.853

7.  Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.

Authors:  T Schilt; M M L de Win; G Jager; M W Koeter; N F Ramsey; B Schmand; W van den Brink
Journal:  Psychol Med       Date:  2007-11-08       Impact factor: 7.723

8.  The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder.

Authors:  M F Ward; P H Wender; F W Reimherr
Journal:  Am J Psychiatry       Date:  1993-06       Impact factor: 18.112

9.  Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.

Authors:  F Indlekofer; M Piechatzek; M Daamen; C Glasmacher; R Lieb; H Pfister; O Tucha; K W Lange; H U Wittchen; C G Schütz
Journal:  J Psychopharmacol       Date:  2008-07-17       Impact factor: 4.153

10.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

View more
  18 in total

1.  fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Authors:  C A Roberts; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2014-11-14       Impact factor: 4.530

2.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

3.  Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).

Authors:  Lynn Taurah; Chris Chandler; Geoff Sanders
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

Review 4.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

5.  Alterations to global but not local motion processing in long-term ecstasy (MDMA) users.

Authors:  Claire White; John Brown; Mark Edwards
Journal:  Psychopharmacology (Berl)       Date:  2014-01-19       Impact factor: 4.530

6.  Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.

Authors:  Daniel W Curry; Matthew B Young; Andrew N Tran; Georges E Daoud; Leonard L Howell
Journal:  Neuropharmacology       Date:  2017-10-06       Impact factor: 5.250

7.  Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing.

Authors:  Tristan J Watkins; Vidya Raj; Junghee Lee; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Ronald M Salomon; Sohee Park; Margaret M Benningfield; Christina R Di Iorio; Ronald L Cowan
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

8.  Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study.

Authors:  Benjamin Becker; Daniel Wagner; Philip Koester; Katja Bender; Christoph Kabbasch; Euphrosyne Gouzoulis-Mayfrank; Jörg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2012-09-23       Impact factor: 4.530

9.  Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion.

Authors:  Craig P Motbey; Emily Karanges; Kong M Li; Shane Wilkinson; Adam R Winstock; John Ramsay; Callum Hicks; Michael D Kendig; Naomi Wyatt; Paul D Callaghan; Iain S McGregor
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.